Abstract
CGG-repeat expansion mutations of the fragile X mental retardation 1 (FMR1) gene are the leading known cause of autism and autism spectrum disorders (ASD). Full mutation expansions ( > 200 CGG repeats) of the gene are generally silenced, resulting in absence of the FMR1 protein and fragile X syndrome. By contrast, smaller expansions in the premutation range (55-200 CGG repeats) result in excess gene activity and RNA toxicity, which is responsible for the neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS), and likely additional cases of developmental delay and autism. Thus, the FMR1 gene is causative of a common (autism) phenotype via two entirely different pathogenic mechanisms, RNA toxicity and gene silencing. The study of this gene and its pathogenic mechanisms therefore represents a paradigm for understanding gene-brain relationships and the means by which diverse genetic mechanisms can give rise to a common behavioral phenotype.
Keywords: fragile X mental retardation 1 gene, Idiopathic Autism, methyl-CpG binding protein, Neuroimaging, CGG repeat
Current Pediatric Reviews
Title: The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments
Volume: 4 Issue: 1
Author(s): Randi J. Hagerman, Susan M. Rivera and Paul J. Hagerman
Affiliation:
Keywords: fragile X mental retardation 1 gene, Idiopathic Autism, methyl-CpG binding protein, Neuroimaging, CGG repeat
Abstract: CGG-repeat expansion mutations of the fragile X mental retardation 1 (FMR1) gene are the leading known cause of autism and autism spectrum disorders (ASD). Full mutation expansions ( > 200 CGG repeats) of the gene are generally silenced, resulting in absence of the FMR1 protein and fragile X syndrome. By contrast, smaller expansions in the premutation range (55-200 CGG repeats) result in excess gene activity and RNA toxicity, which is responsible for the neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS), and likely additional cases of developmental delay and autism. Thus, the FMR1 gene is causative of a common (autism) phenotype via two entirely different pathogenic mechanisms, RNA toxicity and gene silencing. The study of this gene and its pathogenic mechanisms therefore represents a paradigm for understanding gene-brain relationships and the means by which diverse genetic mechanisms can give rise to a common behavioral phenotype.
Export Options
About this article
Cite this article as:
Hagerman J. Randi, Rivera M. Susan and Hagerman J. Paul, The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments, Current Pediatric Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339608783565770
DOI https://dx.doi.org/10.2174/157339608783565770 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endothelin-1 and Endothelin Converting Enzyme-1 in Human Atherosclerosis - Novel Targets for Pharmacotherapy in Atherosclerosis
Current Vascular Pharmacology Potential Application of Gene Therapy to X-Linked Agammaglobulinemia
Current Gene Therapy Insight into Pain Modulation: Nociceptors Sensitization and Therapeutic Targets
Current Drug Targets Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Current Gene Therapy Pidotimod and Immunological Activation in Individuals Infected with HIV
Current HIV Research Natural History of the Nihon Rat Model of BHD
Current Molecular Medicine Malaria-induced Alterations of Drug Kinetics and Metabolism in Rodents and Humans
Current Drug Metabolism Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Current Pharmaceutical Treatments and Alternative Therapies of Parkinson’s Disease
Current Neuropharmacology Motor and Sensory Dysfunction in Musician's Dystonia
Current Neuropharmacology Lipid Nanocarriers and Molecular Targets for Malaria Chemotherapy
Current Drug Targets Heteromerization as a Mechanism Modulating the Affinity of the ACE2 Receptor to the Receptor Binding Domain of SARS-CoV-2 Spike Protein
Current Proteomics The Role of Parthenolide in Intracellular Signalling Processes: Review of Current Knowledge
Current Signal Transduction Therapy The Eker Rat: Establishing a Genetic Paradigm Linking Renal Cell Carcinoma and Uterine Leiomyoma
Current Molecular Medicine Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Mechanisms Involved in Metformin Action in the Treatment of Polycystic Ovary Syndrome
Current Pharmaceutical Design 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Critical Illness in Obstetric Patients: Venous Thromboembolism in Pregnancy
Current Women`s Health Reviews Inflammation-Associated Changes in Bone Homeostasis
Inflammation & Allergy - Drug Targets (Discontinued) Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry